Sexually transmitted infections (STIs) are associated with an increased risk of HIV acquisition and transmission. We estimated the proportion of HIV incidence among men who have sex with men attributable to infection with the two most common bacterial STIs, Neisseria gonorrhoeae (NG) and Chlamydia trachomatis (CT).
We used a stochastic, agent-based model of a sexual network of MSM with co-circulating HIV, NG, and CT infections. Relative risk (RR) multipliers, specific to anatomic site of infection, modified the risk of HIV transmission and acquisition based on STI status. We estimated the effect of NG and CT on HIV incidence overall and on HIV acquisition and HIV transmission separately. Each scenario was simulated for ten years. The population attributable fraction (PAF) was determined for each combination of RRs by comparing the incidence in the final year of a scenario to a scenario in which the RRs associated with NG and CT were set to 1.0.
Overall, 10.4% (IQR: 7.9,12.4) of HIV infections were attributable to NG/CT infection. Then in sensitivity analyses, the PAF for HIV transmission ranged from 3.1% (IQR: 0.5, 5.2) to 20.4% (IQR: 17.8, 22.5) and the PAF for HIV acquisition ranged from 2.0% (IQR: -0.7, 4.3) to 13.8% (IQR: 11.7, 16.0).
Despite challenges in estimating the causal impact of NG/CT on HIV risk, modeling is an alternative approach to quantifying plausible ranges of effects given uncertainty in the biological co-factors. Our estimates represent idealized public health interventions in which STI could be maximally prevented, setting targets for real-world STI interventions that seek to reduce HIV incidence.
Approximately 10% of incident HIV infections among MSM in the US are caused by prevalent gonorrhea or chlamydia infection.
1Department of Epidemiology, Emory University, Atlanta, Georgia
2Centers for Disease Control and Prevention, Atlanta, Georgia
3Department of Epidemiology and Biostatistics, University at Albany, Albany, New York
Corresponding Author: Jeb Jones, PhD, MPH, MS, 1518 Clifton Road, Room GCR 460, Atlanta, Georgia 30322, P: 404-421-2928, F: 404-712-8392. E: email@example.com
No conflicts to disclose.
This work was supported by Centers for Disease Control and Prevention [grant: U38 PS004646], the National Institutes of Health [grants: R01 HD068395, R21 HD075662, R24 HD042828], and the Emory Center for AIDS Research [grant: P30 AI050409].